2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

Posted on by

YANTAI, China, Dec. 12, 2024 /PRNewswire/ — On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session “Novel HER2 Therapeutics” of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. (“RemeGen”) (9995.HK, 688331.SH) presented for the first time the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.